SIRT Is More Cost-Effective Than Sorafenib in Locally Advanced HCC
Investigators compared the cost-effectiveness of selective internal radiotherapy (SIRT) of that of sorafenib in the locally advanced hepatocellular carcinoma setting.
Investigators compared the cost-effectiveness of selective internal radiotherapy (SIRT) of that of sorafenib in the locally advanced hepatocellular carcinoma setting.
The updated CR rate was 8.0% compared with 5.5% in the primary analysis.
Outcomes of lenvatinib-receiving patients who progressed to Child-Pugh B liver function within the first 8 weeks of treatment were compared with those of patients who maintained Child-Pugh A classification during the same time period.
Investigators present findings from a phase 1a study evaluating the safety and efficacy of MIV-818 in patients with hepatocellular carcinoma (HCC), hepatic cholangiocarcinoma (CCA), or liver metastases from solid tumors.
This post hoc analysis of KEYNOTE-240 was performed to determine whether objective response at landmark is prognostic of longer survival after landmark time.
Combination tivozanib and durvalumab was found to be well-tolerated in patients with advanced, treatment-naïve hepatocellular carcinoma (HCC).
Cabozantinib prolonged survival compared with placebo regardless of baseline AFP levels. Lower baseline AFP levels associated with the longest survival.
A trial in progress will evaluate the combination of immunotherapy with tadalafil and vancomycin.
SBRT preserved quality of life and eliminated need for post-TACE hospitalization in patients with hepatocellular carcinoma.
The phase 1b included 104 patients who received lenvatinib 12 mg per day or 8 mg per day plus pembrolizumab 200 mg on day 1 of a 21-day cycle.